Serotonin News and Research

Latest Serotonin News and Research

Exercise improves mood in heart failure patients

Structured exercise achieves modest reductions in depressive symptoms relative to usual care among patients with heart failure, the results of a randomized-controlled trial show.

6 Aug 2012

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.

30 Jul 2012

Insomnia: an interview with Dr Darryle Schoepp

Insomnia is a very common disorder. In medical terms it can affect a third of people. It affects elderly as well as non-elderly people, and is more common in women.

26 Jul 2012

Novel way to monitor real-time chemical changes in brains of patients undergoing DBS

Mayo Clinic researchers have found a novel way to monitor real-time chemical changes in the brains of patients undergoing deep brain stimulation (DBS). The groundbreaking insight will help physicians more effectively use DBS to treat brain disorders such as Parkinson's disease, depression and Tourette syndrome.

16 Jul 2012

Pressure Point develops 72 hour low-cost dermal device to effectively reduce PONV

Pressure Point Inc. has developed an effective 72 hour low-cost, FDA Market Cleared dermal device, which uses an advanced acupressure approach for longer-acting prophylactic results in reducing the occurrences of postoperative nausea and vomiting.

12 Jul 2012

Arena files lorcaserin hydrochloride MAA with Swissmedic

Arena Pharmaceuticals, Inc. announced today the filing with the Swiss health authority, Swissmedic, of a Marketing Authorization Application (MAA) for lorcaserin hydrochloride, an investigational drug candidate in Switzerland.

12 Jul 2012

ACADI’s pimavanserin may have therapeutic benefits in treatment of ADP

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA's proprietary product candidate currently in Phase III development for Parkinson's disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer's disease psychosis (ADP).

10 Jul 2012

Adiponectin reduces depression-like symptoms in mice

A hormone with anti-diabetic properties also reduces depression-like symptoms in mice, researchers from the School of Medicine at the UT Health Science Center San Antonio reported today.

10 Jul 2012

Positive data from Tonix's sublingual TNX-102 PK study for fibromyalgia

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes, including fibromyalgia, reported positive data from an animal pharmacokinetic study of its novel sublingual formulation of TNX-102, the Company's very low dose cyclobenzaprine.

9 Jul 2012

USPTO issues notice of allowance to Avanir for NUEDEXTA

Avanir Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed a new patent that covers Avanir's product NUEDEXTA, further expanding the intellectual property portfolio for the company's lead commercial asset.

2 Jul 2012

Rapamycin enhances learning and memory in young mice

Cognitive skills such as learning and memory diminish with age in everyone, and the drop-off is steepest in Alzheimer's disease. Texas scientists seeking a way to prevent this decline reported exciting results this week with a drug that has Polynesian roots.

30 Jun 2012

Scientists successfully tag serotonin transporter to track movements of single molecules

In a process akin to belling an infinitesimal cat, scientists have managed to tag a protein that regulates the neurotransmitter serotonin with tiny fluorescent beads, allowing them to track the movements of single molecules for the first time.

29 Jun 2012

Millennium introduces novel pharmacogenetic testing

Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain, announced today the introduction of Millennium Pharmacogenetic Testing.

29 Jun 2012

Arena receives FDA approval for Belviq to treat obesity

The U.S. Food and Drug Administration today approved Belviq (lorcaserin hydrochloride), as an addition to a reduced-calorie diet and exercise, for chronic weight management.

28 Jun 2012

Gut microbes regulate brain levels of serotonin

UCC scientists have shown that brain levels of serotonin, the 'happy hormone' are regulated by the amount of bacteria in the gut during early life. Their research is being published today in the leading international psychiatry journal, Molecular Psychiatry.

13 Jun 2012

Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting.

1 Jun 2012

Law aims to illuminate financial links between doctors and pharmaceutical companies

A Colorado School of Public Health researcher has found that laws designed to illuminate financial links between doctors and pharmaceutical companies have little or no effect on what drugs physicians prescribe.

30 May 2012

Positive results from Alkermes’ ALKS 5461 phase 1/2 study on MDD

Alkermes plc today presented positive results from the phase 1/2 study of ALKS 5461, a novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression, in an oral session at the 52nd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting in Phoenix.

30 May 2012

Critically ill patients on antidepressants more likely to die

Researchers at Beth Israel Deaconess Medical Center, in Boston, and the Massachusetts Institute of Technology in Cambridge, have found that critically ill patients were more likely to die if they were taking the most commonly prescribed antidepressants when they were admitted to the intensive care unit (ICU).

23 May 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012